Biomarker sub study of the phase II study of trastuzumab and pertuzumab combination therapy for HER2 amplified advanced solid tumors

Biomarker sub study of the phase II study of trastuzumab and pertuzumab combination therapy for HER2 amplified advanced solid tumors - Biomarker study of HER2 basket study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000037425

Enrollment

Registered

2019-08-01

Start date

2019-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HER2 amplified solid tumor

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Participants of Phase II study Written informed concent

Exclusion criteria

Exclusion criteria: According to Phase II study.

Design outcomes

Primary

Measure	Time frame
Relationships among genomic alterations and response	—

Countries

Japan

Contacts

Public ContactEri Ishibashi

Tokyo Medical and Dental University Medical Innovation center

her2.basket@gmail.com03-3813-6111

Outcome results